Functional relevance of NLRP3 inflammasome-mediated interleukin (IL)-1β during acute allergic airway inflammation

Clinical and Experimental Immunology

Volumn 178, Issue 2, 2014, Pages 212-223

  Ritter, M ^a,b   Straubinger, K ^b   Schmidt, S ^b   Busch, D H ^b,c   Hagner, S ^d   Garn, H ^d   Prazeres da Costa, C ^b   Layland, L E ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Allergy; Anakinra; IL 1 receptor antagonist; IL 1 ; NLRP3 inflammasome

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; CYTOKINE; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; OVALBUMIN; PYCARD PROTEIN, MOUSE;

ACUTE DISEASE; ANIMAL; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; EOSINOPHILIA; FEMALE; GENETICS; GOBLET CELL; HELPER CELL; HYPERPLASIA; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PNEUMONIA; RESPIRATORY HYPERSENSITIVITY;

ACUTE DISEASE; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; EOSINOPHILIA; FEMALE; GOBLET CELLS; HYPERPLASIA; INFLAMMASOMES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MICE; MICE, KNOCKOUT; OVALBUMIN; PNEUMONIA; RECEPTORS, INTERLEUKIN-1 TYPE I; RESPIRATORY HYPERSENSITIVITY; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84908174164     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12400     Document Type: Article

References (57)

1. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-550.
2. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.
3. Larsen CM, Faulenbac M, Vaag A etal. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526.
4. Tillie-Leblond I, Pugin J, Marquette CH etal. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med 1999; 159:487-494.
5. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54:825-857.
6. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol 2005; 32:311-318.
7. Pelaia G, Gallelli L, Renda T etal. Update on optimal use of omalizumab in management of asthma. J Asthma Allergy 2011; 4:49-59.
8. Dolan CM, Fraher KE, Bleecker ER etal. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004; 92:32-39.
9. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002; 3:715-720.
10. Bousquet J, Jeffery PK, Busse WW, Johnson M, Asthma VAM. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161:1720-1745.
11. Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2002; 129:1068-1087.
12. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417-426.
13. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003; 4:95-104.
14. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004; 117:561-574.
15. Ritter M, Gross O, Kays S etal. Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. Proc Natl Acad Sci USA 2010; 107:20459-20464.
16. Hise AG, Tomalka J, Ganesan S etal. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 2009; 5:487-497.
17. Duncan JA, Gao X, Huang MT etal. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol 2009; 182:6460-6469.
18. Mariathasan S, Weiss DS, Newton K etal. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-232.
19. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320:674-677.
20. Hornung V, Bauernfeind F, Halle A etal. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9:847-856.
21. Johnson VJ, Yucesoy B, Luster MI. Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 2005; 116:851-858.
22. Schmitz N, Kurrer M, Kopf M. The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur J Immunol 2003; 33:991-1000.
23. Besnard AG, Guillou N, Tschopp J etal. NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy 2011; 66:1047-1057.
24. Allen IC, Jania CM, Wilson JE etal. Analysis of NLRP3 in the development of allergic airway disease in mice. J Immunol 2012; 188:2884-2893.
25. Whitehead GS, Walker JK, Berman KG, Foster WM, Schwartz DA. Allergen-induced airway disease is mouse strain dependent. Am J Physiol Lung Cell Mol Physiol 2003; 285:L32-42.
26. Kumar RK, Herbert C, Foster PS. The 'classical' ovalbumin challenge model of asthma in mice. Curr Drug Targets 2008; 9:485-494.
27. Zhu W, Gilmour MI. Comparison of allergic lung disease in three mouse strains after systemic or mucosal sensitization with ovalbumin antigen. Immunogenetics 2009; 61:199-207.
28. Swedin L, Ellis R, Kemi C etal. Comparison of aerosol and intranasal challenge in a mouse model of allergic airway inflammation and hyperresponsiveness. Int Arch Allergy Immunol 2010; 153:249-258.
29. Conrad ML, Yildirim AO, Sonar SS etal. Comparison of adjuvant and adjuvant-free murine experimental asthma models. Clin Exp Allergy 2009; 39:1246-1254.
30. Layland LE, Straubinger K, Ritter M etal. Schistosoma mansoni-mediated suppression of allergic airway inflammation requires patency and Foxp3+ Treg cells. PLOS Negl Trop Dis 2013; 7:e2379.
31. Gross O, Yazdi AS, Thomas CJ etal. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36:388-400.
32. Stout-Delgado HW, Vaughan SE, Shirali AC, Jaramillo RJ, Harrod KS. Impaired NLRP3 inflammasome function in elderly mice during influenza infection is rescued by treatment with nigericin. J Immunol 2012; 188:2815-2824.
33. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007; 178:5271-5276.
34. Master SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009; 27:621-668.
35. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20:319-325.
36. Aganna E, Martinon F, Hawkins PN etal. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002; 46:2445-2452.
37. McDermott MF, Tschopp J. From inflammasomes to fevers, crystals and hypertension: how basic research explains inflammatory diseases. Trends Mol Med 2007; 13:381-388.
38. Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol 2011; 166:1-15.
39. Cassel SL, Eisenbarth SC, Lyer SS etal. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008; 105:9035-9040.
40. Delluc A, Limal N, Puéchal X, Francès C, Piette JC, Cacoub P. Efficacy of anakinra, an IL-1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 2008; 67:278-279.
41. Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxf) 2006; 45:491-492.
42. Caucig P, Teschner D, Dinges S etal. Dual role of interleukin-1alpha in delayed-type hypersensitivity and airway hyperresponsiveness. Int Arch Allergy Immunol 2010; 152:303-312.
43. Yamagata S, Tomita K, Sato R, Niwa A, Higashino H, Tohda Y. Interleukin-18-deficient mice exhibit diminished chronic inflammation and airway remodelling in ovalbumin-induced asthma model. Clin Exp Immunol 2008; 154:295-304.
44. Lloyd CM. IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr Opin Immunol 2010; 22:800-806.
45. Kapur S, Bonk ME. Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. P T 2009; 34:138-141.
46. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB etal. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416-2425.
47. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203:1685-1691.
48. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942-949.
49. Guo L, Wei G, Zhu J etal. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci USA 2009; 106:13463-13468.
50. Besnard AG, Togbe D, Couillin I etal. Inflammasome-IL-1-Th17 response in allergic lung inflammation. J Mol Cell Biol 2012; 4:3-10.
51. Kudo M, Melton AC, Chen C etal. IL-17A produced by αβ T cells drives airway hyperresponsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nat Med 2012; 18:547-554.
52. Fogli LK, Sundrud MS, Goel S etal. T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia. J Immunol 2013; 191:3100-3111.
53. Park SJ, Lee YC. Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir Res 2010; 11:78-88.
54. Idzko M, Hammad H, van Nimwegen M etal. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 2007; 13:913-919.
55. Müller T, Vieira RP, Grimm M etal. A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol 2011; 44:456-464.
56. Gasse P, Riteau N, Charron S etal. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009; 179:903-913.
57. Riteau N, Gasse P, Fauconnier L etal. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 2010; 182:774-783.